Consensus on the utility of bone markers in the malignant bone disease setting

Critical Reviews in Oncology/Hematology

Volumn 80, Issue 3, 2011, Pages 411-432

  Coleman, Robert ^a   Costa, Luis ^b   Saad, Fred ^c   Cook, Richard ^d   Hadji, Peyman ^e   Terpos, Evangelos ^f   Garnero, Patrick ^g,h   Brown, Janet ^a,i   Body, Jean Jacques ^j   Smith, Matthew ^k   Lee, Ker Ai ^d   Major, Pierre ^l   Dimopoulos, Meletios ^f   Lipton, Allan ^m  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b HOSPITAL DE SANTA MARIA   (Portugal)

^c CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^d UNIVERSITY OF WATERLOO   (Canada)

^e PHILIPPS UNIVERSITY MARBURG   (Germany)

^f UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^g INSERM   (France)

^h Cisbio Bioassays ^*  (France)

ⁱ UNIVERSITY OF LEEDS   (United Kingdom)

^j BRUGMANN UNIVERSITY HOSPITAL   (Belgium)

^k MASSACHUSETTS GENERAL HOSPITAL   (United States)

^l MCMASTER UNIVERSITY   (Canada)

^m PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

more..

Author keywords

Antiresorptive; Bisphosphonate; Bone marker; Bone metastasis; Bone turnover; Cancer; Osteolysis

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ALKALINE PHOSPHATASE; AMINO TERMINAL PROPEPTIDE OF PROCOLLAGEN TYPE 1; AMINO TERMINAL TELOPEPTIDE; BORTEZOMIB; CARBOXY TERMINAL PROPEPTIDE OF PROCOLLAGEN TYPE 1; CARBOXY TERMINAL TELOPEPTIDE; DENOSUMAB; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PAMIDRONIC ACID; PLACEBO; PROTEIN PRECURSOR; PYRIDINOLINE; TUMOR MARKER; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ADVANCED CANCER; BONE METABOLISM; BONE METASTASIS; BREAST CANCER; CANCER GROWTH; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; CONTINUOUS INFUSION; DISEASE MARKER; DRUG RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; EVIDENCE BASED MEDICINE; FOLLOW UP; HUMAN; IMMUNORADIOMETRIC ASSAY; LUNG NON SMALL CELL CANCER; MORBIDITY; MULTIPLE MYELOMA; PREDICTIVE VALUE; PROGNOSIS; PROSTATE CANCER; PROTEIN BLOOD LEVEL; RADIOIMMUNOASSAY; REVIEW; RISK ASSESSMENT; SOLID TUMOR;

BONE AND BONES; BONE NEOPLASMS; CONSENSUS; HUMANS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 79958775704     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2011.02.005     Document Type: Review

References (188)

1. Coleman R.E. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 2006, 12:6243s-6249s.
2. Kriege M., Seynaeve C., Meijers-Heijboer H., et al. Distant disease-free interval, site of first relapse and post-relapse survival in BRCA1- and BRCA2-associated compared to sporadic breast cancer patients. Breast Cancer Res Treat 2008, 111:303-311.
3. Hess K.R., Varadhachary G.R., Taylor S.H., et al. Metastatic patterns in adenocarcinoma. Cancer 2006, 106:1624-1633.
4. Uchida A., Wakabayashi H., Okuyama N., Okamura A., Matsumine A., Kusuzaki K. Metastatic bone disease: pathogenesis and new strategies for treatment. J Orthop Sci 2004, 9:415-420.
5. Guise T.A., Mohammad K.S., Clines G., et al. Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin Cancer Res 2006, 12:6213s-6216s.
6. Boyce B.F., Yoneda T., Guise T.A. Factors regulating the growth of metastatic cancer in bone. Endocr Relat Cancer 1999, 6:333-347.
7. Chirgwin J.M., Mohammad K.S., Guise T.A. Tumor-bone cellular interactions in skeletal metastases. J Musculoskelet Neuronal Interact 2004, 4:308-318.
8. Guise T.A. Molecular mechanisms of osteolytic bone metastases. Cancer 2000, 88(Suppl.):2892-2898.
9. Guise T.A., Kozlow W.M., Heras-Herzig A., Padalecki S.S., Yin J.J., Chirgwin J.M. Molecular mechanisms of breast cancer metastases to bone. Clin Breast Cancer 2005, 5(Suppl.):S46-S53.
10. Fohr B., Dunstan C.R., Seibel M.J. Clinical review 165: markers of bone remodeling in metastatic bone disease. J Clin Endocrinol Metab 2003, 88:5059-5075.
11. Seibel M.J. Clinical use of markers of bone turnover in metastatic bone disease. Nat Clin Pract Oncol 2005, 2:504-517.
12. Goss P.E., Hadji P., Subar M., Abreu P., Thomsen T., Banke-Bochita J. Effects of steroidal and nonsteroidal aromatase inhibitors on markers of bone turnover in healthy postmenopausal women. Breast Cancer Res 2007, 9:R52.
13. Michaelson M.D., Marujo R.M., Smith M.R. Contribution of androgen deprivation therapy to elevated osteoclast activity in men with metastatic prostate cancer. Clin Cancer Res 2004, 10:2705-2708.
14. Garnero P., Ferreras M., Karsdal M.A., et al. The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation. J Bone Miner Res 2003, 18:859-867.
15. Coleman R., Brown J., Terpos E., et al. Bone markers and their prognostic value in metastatic bone disease: clinical evidence and future directions. Cancer Treat Rev 2008, 34:629-639.
16. Abildgaard N., Glerup H., Rungby J., et al. Biochemical markers of bone metabolism reflect osteoclastic and osteoblastic activity in multiple myeloma. Eur J Haematol 2000, 64:121-129.
17. Alexandrakis M.G., Kyriakou D.S., Passam F.H., Malliaraki N., Vlachonikolis I.G., Karkavitsas N. Urinary N-telopeptide levels in multiple myeloma patients, correlation with Tc-99m-sestaMIBI scintigraphy and other biochemical markers of disease activity. Hematol Oncol 2003, 21:17-24.
18. Ali S.M., Demers L.M., Leitzel K., et al. Baseline serum NTx levels are prognostic in metastatic breast cancer patients with bone-only metastasis. Ann Oncol 2004, 15:455-459.
19. Aruga A., Koizumi M., Hotta R., Takahashi S., Ogata E. Usefulness of bone metabolic markers in the diagnosis and follow-up of bone metastasis from lung cancer. Br J Cancer 1997, 76:760-764.
20. Behrens P., Bruns J., Ullrich K.P., Acil Y., Gille J. Pyridinoline cross-links as markers for primary and secondary bone tumors. Scand J Clin Lab Invest 2003, 63:37-44.
21. Berruti A., Dogliotti L., Tucci M., et al. Metabolic effects of single-dose pamidronate administration in prostate cancer patients with bone metastases. Int J Biol Markers 2002, 17:244-252.
22. Berruti A., Piovesan A., Torta M., et al. Biochemical evaluation of bone turnover in cancer patients with bone metastases: relationship with radiograph appearances and disease extension. Br J Cancer 1996, 73:1581-1587.
23. Berruti A., Torta M., Piovesan A., et al. Biochemical picture of bone metabolism in breast cancer patients with bone metastases. Anticancer Res 1995, 15:2871-2875.
24. Brown J.E., Coleman R.E. Assessment of the effects of breast cancer on bone and the response to therapy. Breast 2002, 11:375-385.
25. Brown J.E., Thomson C.S., Ellis S.P., Gutcher S.A., Purohit O.P., Coleman R.E. Bone resorption predicts for skeletal complications in metastatic bone disease. Br J Cancer 2003, 89:2031-2037.
26. Chung Y.C., Ku C.H., Chao T.Y., Yu J.C., Chen M.M., Lee S.H. Tartrate-resistant acid phosphatase 5b activity is a useful bone marker for monitoring bone metastases in breast cancer patients after treatment. Cancer Epidemiol Biomarkers Prev 2006, 15:424-428.
27. Demers L.M., Costa L., Lipton A. Biochemical markers and skeletal metastases. Cancer 2000, 88(Suppl.):2919-2926.
28. Demers L.M., Costa L., Lipton A. Biochemical markers and skeletal metastases. Clin Orthop Relat Res 2003, (Suppl.):S138-S147.
29. Engler H., Koeberle D., Thuerlimann B., Senn H.J., Riesen W.F. Diagnostic and prognostic value of biochemical markers in malignant bone disease: a prospective study on the effect of bisphosphonate on pain intensity and progression of malignant bone disease. Clin Chem Lab Med 1998, 36:879-885.
30. Fukumitsu N., Uchiyama M., Mori Y., et al. Diagnostic value of urinary N-telopeptide of type I collagen in prostate cancer: comparison with bone scintigraphy. Kaku Igaku 1999, 36:333-339.
31. Hannon R.A., Eastell R. Bone markers and current laboratory assays. Cancer Treat Rev 2006, 32(Suppl. 1):7-14.
32. Hegele A., Wahl H.G., Varga Z., et al. Biochemical markers of bone turnover in patients with localized and metastasized prostate cancer. BJU Int 2007, 99:330-334.
33. Jung K., Lein M., Ringsdorf M., et al. Diagnostic and prognostic validity of serum bone turnover markers in metastatic renal cell carcinoma. J Urol 2006, 176:1326-1331.
34. Jung K., Lein M., Stephan C., et al. Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications. Int J Cancer 2004, 111:783-791.
35. Kanakis I., Nikolaou M., Pectasides D., Kiamouris C., Karamanos N.K. Determination and biological relevance of serum cross-linked type I collagen N-telopeptide and bone-specific alkaline phosphatase in breast metastatic cancer. J Pharm Biomed Anal 2004, 34:827-832.
36. Kiuchi K., Ishikawa T., Hamaguchi Y., et al. Cross-linked collagen C- and N-telopeptides for an early diagnosis of bone metastasis from breast cancer. Oncol Rep 2002, 9:595-598.
37. Koizumi M., Takahashi S., Ogata E. Comparison of serum bone resorption markers in the diagnosis of skeletal metastasis. Anticancer Res 2003, 23:4095-4099.
38. Koizumi M., Takahashi S., Ogata E. Bone metabolic markers in bisphosphonate therapy for skeletal metastases in patients with breast cancer. Breast Cancer 2003, 10:21-27.
39. Koizumi M., Yonese J., Fukui I., Ogata E. The serum level of the amino-terminal propeptide of type I procollagen is a sensitive marker for prostate cancer metastasis to bone. BJU Int 2001, 87:348-351.
40. Koopmans N., de Jong I.J., Breeuwsma A.J., van der Veer E. Serum bone turnover markers (PINP and ICTP) for the early detection of bone metastases in patients with prostate cancer: a longitudinal approach. J Urol 2007, 178:849-853. discussion follows.
41. Leeming D.J., Koizumi M., Byrjalsen I., Li B., Qvist P., Tanko L.B. The relative use of eight collagenous and noncollagenous markers for diagnosis of skeletal metastases in breast, prostate, or lung cancer patients. Cancer Epidemiol Biomarkers Prev 2006, 15:32-38.
42. Lipton A., Cook R.J., Coleman R.E., et al. Clinical utility of biochemical markers of bone metabolism for improving the management of patients with advanced multiple myeloma. Clin Lymphoma Myeloma 2007, 7:346-353.
43. Lipton A., Costa L., Ali S.M., Demers L.M. Bone markers in the management of metastatic bone disease. Cancer Treat Rev 2001, 27:181-185.
44. Lipton A., Demers L., Curley E., et al. Markers of bone resorption in patients treated with pamidronate. Eur J Cancer 1998, 34:2021-2026.
45. Lyubimova N.V., Pashkov M.V., Tyulyandin S.A., Gol'dberg V.E., Kushlinskii N.E. Tartrate-resistant acid phosphatase as a marker of bone metastases in patients with breast cancer and prostate cancer. Bull Exp Biol Med 2004, 138:77-79.
46. Rosen H.N., Moses A.C., Garber J., Ross D.S., Lee S.L., Greenspan S.L. Utility of biochemical markers of bone turnover in the follow-up of patients treated with bisphosphonates. Calcif Tissue Int 1998, 63:363-368.
47. Samani K.K., Brazier M., Mathiot C., et al. Prognostic value of urinary pyridinium crosslinks and their derivatives in multiple myeloma. Ann Hematol 2005, 84:19-24.
48. Silvestris F., Lombardi L., De Matteo M., Bruno A., Dammacco F. Myeloma bone disease: pathogenetic mechanisms and clinical assessment. Leuk Res 2007, 31:129-138.
49. Tamada T., Sone T., Tomomitsu T., Jo Y., Tanaka H., Fukunaga M. Biochemical markers for the detection of bone metastasis in patients with prostate cancer: diagnostic efficacy and the effect of hormonal therapy. J Bone Miner Metab 2001, 19:45-51.
50. Terpos E. Biochemical markers of bone metabolism in multiple myeloma. Cancer Treat Rev 2006, 32(Suppl. 1):15-19.
51. Terpos E., Politou M., Rahemtulla A. The role of markers of bone remodeling in multiple myeloma. Blood Rev 2005, 19:125-142.
52. Ulrich U., Rhiem K., Schmolling J., et al. Cross-linked type I collagen C- and N-telopeptides in women with bone metastases from breast cancer. Arch Gynecol Obstet 2001, 264:186-190.
53. Vinholes J., Guo C.Y., Purohit O.P., Eastell R., Coleman R.E. Evaluation of new bone resorption markers in a randomized comparison of pamidronate or clodronate for hypercalcemia of malignancy. J Clin Oncol 1997, 15:131-138.
54. Voorzanger-Rousselot N., Juillet F., Mareau E., Zimmermann J., Kalebic T., Garnero P. Association of 12 serum biochemical markers of angiogenesis, tumour invasion and bone turnover with bone metastases from breast cancer: a crossectional and longitudinal evaluation. Br J Cancer 2006, 95:506-514.
55. Heider U., Fleissner C., Zavrski I., et al. Bone markers in multiple myeloma. Eur J Cancer 2006, 42:1544-1553.
56. Pectasides D., Farmakis D., Nikolaou M., et al. Diagnostic value of bone remodeling markers in the diagnosis of bone metastases in patients with breast cancer. J Pharm Biomed Anal 2005, 37:171-176.
57. Karayannopoulou M., Polizopoulou Z.S., Koutinas A.F., et al. Serum alkaline phosphatase isoenzyme activities in canine malignant mammary neoplasms with and without osseous transformation. Vet Clin Pathol 2006, 35:287-290.
58. Izumi M., Nakanishi Y., Takayama K., et al. Diagnostic value of bone-turnover metabolites in the diagnosis of bone metastases in patients with lung carcinoma. Cancer 2001, 91:1487-1493.
59. Tanko L.B., Karsdal M.A., Christiansen C., Leeming D.J. Biochemical approach to the detection and monitoring of metastatic bone disease: what do we know and what questions need answers?. Cancer Metastasis Rev 2006, 25:659-668.
60. Chrapko B.E., Nocun A., Golebiewska R., Jankowska H., Zaorska-Rajca J. Bone turnover markers and bone scintigraphy in the evaluation of the skeletal metastases. Nucl Med Rev Cent East Eur 2005, 8:100-104.
61. Palma M.A., Body J.J. Usefulness of bone formation markers in breast cancer. Int J Biol Markers 2005, 20:146-155.
62. Coleman R.E. Bisphosphonates: clinical experience. Oncologist 2004, 9(Suppl. 4):14-27.
63. Terpos E., de la Fuente J., Szydlo R., et al. Tartrate-resistant acid phosphatase isoform 5b: a novel serum marker for monitoring bone disease in multiple myeloma. Int J Cancer 2003, 106:455-457.
64. Martinetti A., Ripamonti C., Miceli R., et al. Short-term effects of pamidronate on bone turnover: can bone markers be considered predictive of the analgesic response?. Oncol Rep 2007, 17:1533-1540.
65. Berruti A., Dogliotti L., Gorzegno G., et al. Differential patterns of bone turnover in relation to bone pain and disease extent in bone in cancer patients with skeletal metastases. Clin Chem 1999, 45:1240-1247.
66. Suzuki Y., Tokuda Y., Saito Y., Umemura S., Osamura R.Y. Clinicopathological correlation between expression of PTHrP receptor and various prognostic factors in breast cancer without axillary lymph node metastasis. Tokai J Exp Clin Med 2005, 30:127-132.
67. Kailajarvi M.E., Salminen E.K., Paija O.M., Virtanent A.M., Leino A.E., Irjala K.A. Serum bone markers in breast cancer patients during 5-fluorouracil, epirubicin and cyclophosphamide (FEC) therapy. Anticancer Res 2004, 24:1271-1274.
68. Seibel M.J., Naganathan V., Barton I., Grauer A. Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate. J Bone Miner Res 2004, 19:323-329.
69. Erem C., Tanakol R., Alagol F., Omer B., Cetin O. Relationship of bone turnover parameters, endogenous hormones and vit D deficiency to hip fracture in elderly postmenopausal women. Int J Clin Pract 2002, 56:333-337.
70. Bauer D.C., Garnero P., Bilezikian J.P., et al. Short-term changes in bone turnover markers and bone mineral density response to parathyroid hormone in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2006, 91:1370-1375.
71. Iwamoto J., Takeda T., Sato Y., Uzawa M. Determinants of one-year response of lumbar bone mineral density to alendronate treatment in elderly Japanese women with osteoporosis. Yonsei Med J 2004, 45:676-682.
72. Yamazaki S., Ichimura S., Iwamoto J., Takeda T., Toyama Y. Effect of walking exercise on bone metabolism in postmenopausal women with osteopenia/osteoporosis. J Bone Miner Metab 2004, 22:500-508.
73. Ravn P., Thompson D.E., Ross P.D., Christiansen C. Biochemical markers for prediction of 4-year response in bone mass during bisphosphonate treatment for prevention of postmenopausal osteoporosis. Bone 2003, 33:150-158.
74. Bergmann P., Body J.J., Boonen S., et al. Evidence-based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of bisphosphonate treatment in osteoporosis: a consensus document of the Belgian Bone Club. Int J Clin Pract 2009, 63:19-26.
75. Voorzanger-Rousselot N., Garnero P. Biochemical markers in oncology. Part I: molecular basis. Part II: clinical uses. Cancer Treat Rev 2007, 33:230-283.
76. Zhu L., Loo W.T., Cheng C.W., Chow L.W. Possible predictive markers related to micro-metastasis in breast cancer patients. Oncol Rep 2006, 15:1217-1223.
77. Faderl S., Talpaz M., Estrov Z., O'Brien S., Kurzrock R., Kantarjian H.M. The biology of chronic myeloid leukemia. N Engl J Med 1999, 341:164-172.
78. Goldman J.M., Melo J.V. Chronic myeloid leukemia-advances in biology and new approaches to treatment. N Engl J Med 2003, 349:1451-1464.
79. Roberts S.G., Blute M.L., Bergstralh E.J., Slezak J.M., Zincke H. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer. Mayo Clin Proc 2001, 76:576-581.
80. Swindle P.W., Kattan M.W., Scardino P.T. Markers and meaning of primary treatment failure. Urol Clin North Am 2003, 30:377-401.
81. Choueiri T.K. Factors associated with outcome in patients with advanced renal cell carcinoma in the era of antiangiogenic agents. Clin Genitourin Cancer 2008, 6:15-20.
82. Moehler M., Frings C., Mueller A., et al. VEGF-D expression correlates with colorectal cancer aggressiveness and is downregulated by cetuximab. World J Gastroenterol 2008, 14:4156-4167.
83. Smith M.R., Kabbinavar F., Saad F., et al. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol 2005, 23:2918-2925.
84. Costa L., Demers L.M., Gouveia-Oliveira A., et al. Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status. J Clin Oncol 2002, 20:850-856.
85. Coleman R., Cook R., Saad F., et al. Meta-analysis of effects of zoledronic acid on survival in patients with metastatic bone disease (MBD) and high bone turnover. Cancer Treat Rev 2008, 34(Suppl.):S86. [abstract P81].
86. Brown J.E., Cook R.J., Major P., et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 2005, 97:59-69.
87. Coleman R.E., Major P., Lipton A., et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 2005, 23:4925-4935.
88. Lipton A., Cook R.J., Major P., Smith M.R., Coleman R.E. Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity. Oncologist 2007, 12:1035-1043.
89. Lipton A., Cook R., Saad F., et al. Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Cancer 2008, 113:193-201.
90. Garnero P., Buchs N., Zekri J., Rizzoli R., Coleman R.E., Delmas P.D. Markers of bone turnover for the management of patients with bone metastases from prostate cancer. Br J Cancer 2000, 82:858-864.
91. Lipton A., Chapman J.W., Demers L., et al. Use of elevated bone turnover to predict bone metastasis. J Clin Oncol 2008, 26(Suppl.):28s. [abstract 591].
92. Hou M.F., Tsai L.Y., Tsai S.M., et al. Biochemical markers for assessment of bone metastases in patients with breast cancer. Kaohsiung J Med Sci 1999, 15:452-460.
93. Heller W., Harzmann R., Bichler K.H., Schmidt K. Urinary hydroxyproline in healthy patients and in prostate patients with and without bone metastases. Curr Probl Clin Biochem 1979, 249-256.
94. Stepan J.J., Mikulecky M., Bek V., Broulik P., Pacovsky V. Bone alkaline phosphatase isoenzyme and urinary hydroxyproline in healthy subjects, patients with osteolytic metastases, and patients with primary hyperparathyroidism. Neoplasma 1989, 36:495-501.
95. Desoize B., Veiler V., Pourny C., Comoe L., Jardillier J.C. Isoenzymes of alkaline and acid phosphatases as bones metastasis marker in breast cancer patients. Anticancer Res 1989, 9:1105-1109.
96. Capeller B., Caffier H., Sutterlin M.W., Dietl J. Evaluation of tartrate-resistant acid phosphatase (TRAP) 5b as serum marker of bone metastases in human breast cancer. Anticancer Res 2003, 23:1011-1015.
97. Fonseca R., Trendle M.C., Leong T., et al. Prognostic value of serum markers of bone metabolism in untreated multiple myeloma patients. Br J Haematol 2000, 109:24-29.
98. Lorente J.A., Valenzuela H., Morote J., Gelabert A. Serum bone alkaline phosphatase levels enhance the clinical utility of prostate specific antigen in the staging of newly diagnosed prostate cancer patients. Eur J Nucl Med 1999, 26:625-632.
99. Smith M.R., Cook R.J., Coleman R., et al. Predictors of skeletal complications in men with hormone-refractory metastatic prostate cancer. Urology 2007, 70:315-319.
100. Cook R.J., Coleman R., Brown J., et al. Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer. Clin Cancer Res 2006, 12:3361-3367.
101. Domchek S.M., Younger J., Finkelstein D.M., Seiden M.V. Predictors of skeletal complications in patients with metastatic breast carcinoma. Cancer 2000, 89:363-368.
102. Bellahcene A., Menard S., Bufalino R., Moreau L., Castronovo V. Expression of bone sialoprotein in primary human breast cancer is associated with poor survival. Int J Cancer 1996, 69:350-353.
103. Slovik D.M., Gundberg C.M., Neer R.M., Lian J.B. Clinical evaluation of bone turnover by serum osteocalcin measurements in a hospital setting. J Clin Endocrinol Metab 1984, 59:228-230.
104. Hirsh V., Major P.P., Lipton A., et al. Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity. J Thorac Oncol 2008, 3:228-236.
105. Rosen L.S., Gordon D., Kaminski M., et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 2003, 98:1735-1744.
106. Rosen L.S., Gordon D., Tchekmedyian N.S., et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer 2004, 100:2613-2621.
107. Saad F., Gleason D.M., Murray R., et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004, 96:879-882.
108. Fizazi K., Lipton A., Mariette X., et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol 2009, 27:1564-1571.
109. Lipton A., Steger G.G., Figueroa J., et al. Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J Clin Oncol 2007, 25:4431-4437.
110. Hannon R.A., Clack G., Rimmer M., et al. Effects of the Src kinase inhibitor saracatinib (AZD0530) on bone turnover in healthy men: a randomized, double-blind, placebo-controlled, multiple-ascending-dose phase I trial. J Bone Miner Res 2010, 25:463-471.
111. Lindsey A.M., Piper B.F. Anorexia and weight loss: indicators of cachexia in small cell lung cancer. Nutr Cancer 1985, 7:65-76.
112. Generali D., Berruti A., Tampellini M., et al. The circadian rhythm of biochemical markers of bone resorption is normally synchronized in breast cancer patients with bone lytic metastases independently of tumor load. Bone 2007, 40:182-188.
113. Kikuchi E., Nakashima J., Ishibashi M., et al. Usefulness of alpha1-antichymotrypsin-PSA complex for predicting bone metastases of prostate cancer. Urology 2006, 68:371-375.
114. Nishio Y., Yamada Y., Kokubo H., et al. Prognostic significance of immunohistochemical expression of the HER-2/neu oncoprotein in bone metastatic prostate cancer. Urology 2006, 68:110-115.
115. Lawless J.F. Statistical models and methods for lifetime data 2002, Wiley-Interscience, Hoboken, NJ. 2nd edition.
116. Cannon C.P. Clinical perspectives on the use of composite endpoints. Control Clin Trials 1997, 18:517-529. discussion follows.
117. Chi G.Y. Some issues with composite endpoints in clinical trials. Fundam Clin Pharmacol 2005, 19:609-619.
118. Ferreira-Gonzalez I., Permanyer-Miralda G., Busse J.W., et al. Methodologic discussions for using and interpreting composite endpoints are limited, but still identify major concerns. J Clin Epidemiol 2007, 60:651-657. discussion follows.
119. Crowder M.J. Classical competing risks 2001, Chapman and Hall/CRC, London.
120. Therneau T., Grambsch P. Modeling survival data: extending the Cox model 2000, Springer, New York.
121. Andersen P.K., Gill R.D. Cox's regression model for counting processes: a large sample study. Ann Stat 1982, 10:1100-1120.
122. Cook R.J., Lawless J.F. The statistical analysis of recurrent events 2007, Springer, New York.
123. Harris L., Fritsche H., Mennel R., et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007, 25:5287-5312.
124. Hillner B.E., Ingle J.N., Berenson J.R., et al. American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel. J Clin Oncol 2000, 18:1378-1391.
125. Brown J.E., McCloskey E.V., Dewar J.A., et al. The use of bone markers in a 6-week study to assess the efficacy of oral clodronate in patients with metastatic bone disease. Calcif Tissue Int 2007, 81:341-351.
126. Jensen B.V., Johansen J.S., Skovsgaard T., Brandt J., Teisner B. Extracellular matrix building marked by the N-terminal propeptide of procollagen type I reflect aggressiveness of recurrent breast cancer. Int J Cancer 2002, 98:582-589.
127. Oremek G., Sauer-Eppel H., Klepzig M. Total procollagen type 1 amino-terminal propeptide (total P1NP) as a bone metastasis marker in gynecological carcinomas. Anticancer Res 2007, 27:1961-1962.
128. Thurairaja R., Iles R.K., Jefferson K., McFarlane J.P., Persad R.A. Serum amino-terminal propeptide of type 1 procollagen (P1NP) in prostate cancer: a potential predictor of bone metastases and prognosticator for disease progression and survival. Urol Int 2006, 76:67-71.
129. Jukkola A., Tahtela R., Tholix E., et al. Aggressive breast cancer leads to discrepant serum levels of the type I procollagen propeptides PINP and PICP. Cancer Res 1997, 57:5517-5520.
130. Ylisirnio S., Sassi M.L., Risteli J., Turpeenniemi-Hujanen T., Jukkola A. Serum type I collagen degradation markers, ICTP and CrossLaps, are factors for poor survival in lung cancer. Anticancer Res 1999, 19:5577-5581.
131. McCloskey E., Paterson A., Kanis J., Tahtela R., Powles T. Effect of oral clodronate on bone mass, bone turnover and subsequent metastases in women with primary breast cancer. Eur J Cancer 2010, 46:558-565.
132. Vinholes J.J., Purohit O.P., Abbey M.E., Eastell R., Coleman R.E. Relationships between biochemical and symptomatic response in a double-blind randomised trial of pamidronate for metastatic bone disease. Ann Oncol 1997, 8:1243-1250.
133. Brufsky A., Harker G., Beck T., et al. Bone-specific alkaline phosphatase (BSAP) and serum N-telopeptide (sNTX) as predictors of bone loss in postmenopausal women with early breast cancer receiving letrozole as adjuvant therapy: a 5-year study (Z-FAST). Cancer Res 2009, 69(Suppl.):176s. [abstract 2067].
134. Greenspan S.L., Coates P., Sereika S.M., Nelson J.B., Trump D.L., Resnick N.M. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J Clin Endocrinol Metab 2005, 90:6410-6417.
135. Smith M.R., Fallon M.A., Goode M.J. Cross-sectional study of bone turnover during bicalutamide monotherapy for prostate cancer. Urology 2003, 61:127-131.
136. Ishizaka K., Machida T., Kobayashi S., Kanbe N., Kitahara S., Yoshida K. Preventive effect of risedronate on bone loss in men receiving androgen-deprivation therapy for prostate cancer. Int J Urol 2007, 14:1071-1075.
137. Israeli R.S., Rosenberg S.J., Saltzstein D.R., et al. The effect of zoledronic acid on bone mineral density in patients undergoing androgen deprivation therapy. Clin Genitourin Cancer 2007, 5:271-277.
138. Magno C., Anastasi G., Morabito N., et al. Preventing bone loss during androgen deprivation therapy for prostate cancer: early experience with neridronate. Eur Urol 2005, 47:575-580. discussion follows.
139. Chen T., Berenson J., Vescio R., et al. Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J Clin Pharmacol 2002, 42:1228-1236.
140. Sato M., Grasser W., Endo N., et al. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 1991, 88:2095-2105.
141. Azuma Y., Sato H., Oue Y., et al. Alendronate distributed on bone surfaces inhibits osteoclastic bone resorption in vitro and in experimental hypercalcemia models. Bone 1995, 16:235-245.
142. Cremers S.C., Papapoulos S.E., Gelderblom H., et al. Skeletal retention of bisphosphonate (pamidronate) and its relation to the rate of bone resorption in patients with breast cancer and bone metastases. J Bone Miner Res 2005, 20:1543-1547.
143. Nancollas G.H., Tang R., Phipps R.J., et al. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone 2006, 38:617-627.
144. Russell R.G. Determinants of structure-function relationships among bisphosphonates. Bone 2007, 40:S21-S25.
145. Coxon F.P., Thompson K., Roelofs A.J., Ebetino F.H., Rogers M.J. Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and non-resorbing cells. Bone 2008, 42:848-860.
146. U.S. National Institutes of Health. Efficacy and safety of zoledronic acid (every 4weeks vs. every 12weeks) in patients with documented metastases from bone cancer, [accessed 18.08.10]. http://www.clinicaltrials.gov/ct2/show/NCT00320710.
147. U.S. National Institutes of Health. Zoledronic acid treatment (every 4 or 12weeks) to prevent selected complications in advanced multiple myeloma patients (Z-MARK), [accessed 18.08.10]. http://www.clinicaltrials.gov/ct2/show/NCT00622505.
148. U.S. National Institutes of Health. Comparison of two schedules of zoledronic acid in treating patients with breast cancer that has spread to the bone, [accessed 18.08.10]. http://www.clinicaltrials.gov/ct2/show/NCT00458796.
149. Abildgaard N., Brixen K., Eriksen E.F., Kristensen J.E., Nielsen J.L., Heickendorff L. Sequential analysis of biochemical markers of bone resorption and bone densitometry in multiple myeloma. Haematologica 2004, 89:567-577.
150. Alexandrakis M.G., Passam F.H., Malliaraki N., Katachanakis C., Kyriakou D.S., Margioris A.N. Evaluation of bone disease in multiple myeloma: a correlation between biochemical markers of bone metabolism and other clinical parameters in untreated multiple myeloma patients. Clin Chim Acta 2002, 325:51-57.
151. Carlson K., Larsson A., Simonsson B., Turesson I., Westin J., Ljunghall S. Evaluation of bone disease in multiple myeloma: a comparison between the resorption markers urinary deoxypyridinoline/creatinine (DPD) and serum ICTP, and an evaluation of the DPD/osteocalcin and ICTP/osteocalcin ratios. Eur J Haematol 1999, 62:300-306.
152. Dizdar O., Barista I., Kalyoncu U., et al. Biochemical markers of bone turnover in diagnosis of myeloma bone disease. Am J Hematol 2007, 82:185-191.
153. Goranova-Marinova V., Goranov S., Pavlov P., Tzvetkova T. Serum levels of OPG, RANKL and RANKL/OPG ratio in newly-diagnosed patients with multiple myeloma. Clinical correlations. Haematologica 2007, 92:1000-1001.
154. Jakob C., Zavrski I., Heider U., et al. Bone resorption parameters [carboxy-terminal telopeptide of type-I collagen (ICTP), amino-terminal collagen type-I telopeptide (NTx), and deoxypyridinoline (Dpd)] in MGUS and multiple myeloma. Eur J Haematol 2002, 69:37-42.
155. Kuliszkiewicz-Janus M., Malecki R., Zoltaszek A., Zastawny M. The significance of carboxy-terminal telopeptide of type I collagen (ICTP) and osteocalcin (OC) in assessment of bone disease in patients with multiple myeloma. Leuk Lymphoma 2005, 46:1749-1753.
156. Terpos E., Szydlo R., Apperley J.F., et al. Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Blood 2003, 102:1064-1069.
157. Zangari M., Esseltine D., Cavallo F., et al. Predictive value of alkaline phosphatase for response and time to progression in bortezomib-treated multiple myeloma patients. Am J Hematol 2007, 82:831-833.
158. Terpos E., Berenson J., Cook R.J., Lipton A., Coleman R.E. Prognostic variables for survival and skeletal complications in patients with multiple myeloma osteolytic bone disease. Leukemia 2010, 24:1043-1049.
159. Lund T., Abildgaard N., Andersen T.L., Delaisse J.M., Plesner T. Multiple myeloma: changes in serum C-terminal telopeptide of collagen type I and bone-specific alkaline phosphatase can be used in daily practice to detect imminent osteolysis. Eur J Haematol 2010, 84:412-420.
160. Jakob C., Sterz J., Liebisch P., et al. Incorporation of the bone marker carboxy-terminal telopeptide of type-1 collagen improves prognostic information of the International Staging System in newly diagnosed symptomatic multiple myeloma. Leukemia 2008, 22:1767-1772.
161. Schutt P., Rebmann V., Brandhorst D., et al. The clinical significance of soluble human leukocyte antigen class-I, ICTP, and RANKL molecules in multiple myeloma patients. Hum Immunol 2008, 69:79-87.
162. Terpos E., Dimopoulos M.A., Sezer O. The effect of novel anti-myeloma agents on bone metabolism of patients with multiple myeloma. Leukemia 2007, 21:1875-1884.
163. Terpos E., Mihou D., Szydlo R., et al. The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL/osteoprotegerin ratio. Leukemia 2005, 19:1969-1976.
164. Terpos E., Kastritis E., Roussou M., et al. The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis. Leukemia 2008, 22:2247-2256.
165. Chung J.H., Park M.S., Kim Y.S., et al. Usefulness of bone metabolic markers in the diagnosis of bone metastasis from lung cancer. Yonsei Med J 2005, 46:388-393.
166. Ebert W., Muley T., Herb K.P., Schmidt-Gayk H. Comparison of bone scintigraphy with bone markers in the diagnosis of bone metastasis in lung carcinoma patients. Anticancer Res 2004, 24:3193-3201.
167. Korpela J., Tiitinen S.L., Hiekkanen H., et al. Serum TRACP 5b and ICTP as markers of bone metastases in breast cancer. Anticancer Res 2006, 26:3127-3132.
168. Urwin G.H., Percival R.C., Yates A.J., et al. Biochemical markers and skeletal metabolism in carcinoma of the prostate. Use of decision matrix theory and ROC analysis. Br J Urol 1985, 57:711-714.
169. Wada N., Fujisaki M., Ishii S., Ikeda T., Kitajima M. Evaluation of bone metabolic markers in breast cancer with bone metastasis. Breast Cancer 2001, 8:131-137.
170. Westerhuis L.W., Delaere K.P. Diagnostic value of some biochemical bone markers for the detection of bone metastases in prostate cancer. Eur J Clin Chem Clin Biochem 1997, 35:89-94.
171. Kong Q.Q., Sun T.W., Dou Q.Y., et al. Beta-CTX and ICTP act as indicators of skeletal metastasis status in male patients with non-small cell lung cancer. Int J Biol Markers 2007, 22:214-220.
172. Klepzig M., Jonas D., Oremek G.M. Procollagen type 1 amino-terminal propeptide: a marker for bone metastases in prostate carcinoma. Anticancer Res 2009, 29:671-673.
173. Aapro M., Abrahamsson P.A., Body J.J., et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol 2008, 19:420-432.
174. Papotti M., Kalebic T., Volante M., et al. Bone sialoprotein is predictive of bone metastases in resectable non-small-cell lung cancer: a retrospective case-control study. J Clin Oncol 2006, 24:4818-4824.
175. Bellahcene A., Kroll M., Liebens F., Castronovo V. Bone sialoprotein expression in primary human breast cancer is associated with bone metastases development. J Bone Miner Res 1996, 11:665-670.
176. Nam J.S., Suchar A.M., Kang M.J., et al. Bone sialoprotein mediates the tumor cell-targeted prometastatic activity of transforming growth factor beta in a mouse model of breast cancer. Cancer Res 2006, 66:6327-6335.
177. Kayed H., Kleeff J., Keleg S., et al. Effects of bone sialoprotein on pancreatic cancer cell growth, invasion and metastasis. Cancer Lett 2007, 245:171-183.
178. Chaplet M., Waltregny D., Detry C., Fisher L.W., Castronovo V., Bellahcene A. Expression of dentin sialophosphoprotein in human prostate cancer and its correlation with tumor aggressiveness. Int J Cancer 2006, 118:850-856.
179. Loibl S., Konigs A., Kaufmann M., Costa S.D., Bischoff J. PTHrP and bone sialoprotein as prognostic markers for developing bone metastases in breast cancer patients. Zentralbl Gynakol 2006, 128:330-335.
180. Dean-Colomb W., Esteva F.J. Her2-positive breast cancer: herceptin and beyond. Eur J Cancer 2008, 44:2806-2812.
181. Mihai R., Stevens J., McKinney C., Ibrahim N.B. Expression of the calcium receptor in human breast cancer-a potential new marker predicting the risk of bone metastases. Eur J Surg Oncol 2006, 32:511-515.
182. Nowicki M., Ostalska-Nowicka D., Miskowiak B. Prognostic value of stage IV neuroblastoma metastatic immunophenotype in the bone marrow: preliminary report. J Clin Pathol 2006, 59:150-152.
183. Dobashi Y., Watanabe H., Matsubara M., et al. Autocrine motility factor/glucose-6-phosphate isomerase is a possible predictor of metastasis in bone and soft tissue tumours. J Pathol 2006, 208:44-53.
184. Naruse K., Yamada Y., Aoki S., et al. Lactate dehydrogenase is a prognostic indicator for prostate cancer patients with bone metastasis. Hinyokika Kiyo 2007, 53:287-292.
185. Rajkumar S.V., Kyle R.A. Multiple myeloma: diagnosis and treatment. Mayo Clin Proc 2005, 80:1371-1382.
186. Fang N., Li Y., Xu Y.S., et al. Serum concentrations of IL-2 and TNF-alpha in patients with painful bone metastases: correlation with responses to 89SrCl2 therapy. J Nucl Med 2006, 47:242-246.
187. Costa L.A., Alho I., Casimiro S., et al. Markers of bone turnover (ICTP, NTX) and serum matrix metalloproteinase 1 (MMP1) as prognostic markers in breast cancer patients (BC) with bone metastases (BM) treated with bisphosphonates (BP). J Clin Oncol 2008, 26(Suppl.):47s. [abstract 1024].
188. Terpos E., Katodritou E., Tsiftsakis E., et al. Cystatin-C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administration. Haematologica 2009, 94:372-379.